The safety and efficacy of thalidomide in IBD has been recently evaluated in several open-label studies both adults and children, some of which with a long-term follow up. A total of approximately 200 patients with steroid-resistant or steroid-dependent IBD were treated with thalidomide. Overall, the drug was effective in inducing clinical remission in 20-70% of patients (average of 40%). 60-100% patients (average of 70%) had some clinical response. Steroid-tapering was possible in 60-100% of cases.